Quick Order Cart

Cat. No. ARG1616

CLTA Knockout Raji Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone

  • Disease:

    Burkitt lymphoma

The CLTA Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population of human Raji B lymphocytes with targeted disruption of the CLTA gene, encoding clathrin light chain A. This model provides a powerful tool for dissecting clathrin-mediated endocytosis in a B-cell context. CLTA cooperates with clathrin heavy chain, AP-2, and dynamin to internalize cargo such as EGFR and transferrin receptor; its loss disrupts receptor trafficking and downstream signaling. These cells are ideal for receptor internalization assays, lymphoma studies, and endocytic pathway analysis using techniques like transferrin uptake, flow cytometry, and co-imiprecipitation.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Raji

    Cell Type

    B cell line

    Sex of Donor

    Male

    Age

    11 years

    Derived From Site

    In situ; Maxilla

    Gene Name

    CLTA

    Gene Identifier

    NCBI Gene ID 1211

    Morphology

    Lymphoblast-like

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The CLTA Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of human Raji B lymphocytes in which the CLTA gene has been disrupted. This loss-of-function model abolishes expression of clathrin light chain A across a heterogeneous cell pool, enabling investigation of clathrin-mediated endocytosis without the constraints of monoclonal selection. The polyclonal format reflects the diversity of editing outcomes while preserving the parental line??s characteristics. It provides a robust platform for studying clathrin-dependent internalization processes in a B-cell context.

The Raji cell line originates from Burkitt??s lymphoma, possessing an EBV-positive background and a c-MYC translocation that drives rapid proliferation. These B lymphocytes retain key immune functions, including antigen presentation and antibody production, making them a relevant model for lymphoma and adaptive immunity research. In this setting, CLTA knockout allows dissection of how clathrin machinery modulates receptor dynamics and signaling in malignant B cells, offering insights into pathways that sustain tumor growth.

CLTA forms heterotrimers with clathrin heavy chain (CLTC) and CLTB, essential for clathrin-mediated endocytosis. It interacts with HIP1, AP-2, epsin, dynamin (DNM1/DNM2), and auxilin to drive vesicle formation. Upstream regulation involves EGFR, transferrin receptor, and AP-2, while downstream cargo includes EGFR, Notch, transferrin receptor, GPCRs, and Toll-like receptors. CLTA knockout disrupts receptor internalization, impairing endosomal trafficking and altering EGFR and Notch signaling pathways, offering a tool to dissect clathrin-dependent trafficking in signal transduction.

In Raji B cells, CLTA knockout impairs antigen internalization and receptor turnover, processes vital for B-cell receptor signaling and immune function. Given that Notch and EGFR signaling intersect with c-MYC-driven proliferation, this model elucidates how endocytic defects may influence lymphoma maintenance. Additionally, clathrin-dependent TLR trafficking impacts innate immune responses in EBV-positive lymphomas. Thus, the knockout cells serve as a valuable tool for exploring the interplay between endocytosis and oncogenic signaling in B-cell malignancies.

These cells are suited for transferrin uptake and EGFR internalization assays, flow cytometric monitoring of surface receptors, and RNA-seq profiling. They enable studies on receptor trafficking, nanoparticle uptake, and drug delivery, alongside functional assays like proliferation and apoptosis measurements. Co-immunoprecipitation and electron microscopy can probe protein interactions. For further information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)